Dual Marker (Blood Test)

A dual marker blood test is a first‑trimester prenatal screening done around 9–13 weeks that measures two pregnancy proteins—pregnancy‑associated plasma protein A (PAPP‑A) and free beta‑hCG—to estimate the baby’s risk of chromosomal conditions such as Down syndrome and trisomy 18. It’s a risk assessment, not diagnostic; abnormal results prompt offer of noninvasive prenatal testing or diagnostic procedures.

If a double-marker test is positive, it indicates increased risk, not a diagnosis. Next steps: see a specialist for genetic counseling, get a detailed fetal ultrasound, and consider noninvasive prenatal testing (cell‑free DNA). For definitive diagnosis, discuss invasive testing (CVS in the first trimester or amniocentesis later). Review maternal factors and plan follow‑up and management.

No. A double‑marker test is a screening—not diagnostic—tool and isn’t 100% accurate. Depending on whether it’s used alone or combined with a nuchal translucency scan, detection rates for chromosomal abnormalities range roughly from about 60% to around 90%, with some false positives and negatives. Abnormal or high‑risk results require confirmatory testing (cell‑free DNA or diagnostic CVS/amniocentesis).

Dual‑marker prenatal screening is best done between 9 and 13 weeks of pregnancy, with optimal accuracy at 11–13 weeks (up to 13 weeks + 6 days). This timing yields reliable PAPP‑A and free β‑hCG results and can be paired with nuchal translucency ultrasound. Tests after 14 weeks are less informative; confirm exact timing and follow‑up with your obstetrician.

Risk of trisomy 21 (Down syndrome) rises with maternal age. At age 20 the chance is about 1 in 1,500; at 30 about 1 in 900–1,000; at 35 roughly 1 in 350; at 40 about 1 in 100; and by 45 around 1 in 30. Paternal age has a smaller effect; screening and diagnostic tests can assess individual risk.

You can’t completely prevent chromosomal abnormalities (often random), but you can reduce risk and detect them early: seek preconception genetic counseling and parental karyotyping if there’s family history or recurrent miscarriage; consider carrier screening and IVF with preimplantation genetic testing (PGT‑A); optimize maternal health (control chronic illness, avoid smoking/alcohol/drugs, maintain healthy weight); and undergo prenatal screening (NIPT) and diagnostic testing as advised.